Clinical features of stage T_1 HER2-positive breast cancer patients and analysis of-positive the prognostic effect of anti-HER2 targeted therapy
WANG Fenglian;CHENG Xufeng;ZHAO Huiduo;WU Bing;Department of Breast Oncology, the First Affiliated Hospital of He'nan Traditional Chinese Medicine University;
Objective To summarize the clinicopathological features of stage T1 HER2-positive breast cancer and to analyze the prognostic effect of anti-HER2 targeted therapy. Method A total of 50 cases of stage T, HER2-positive breast cancer patients were included in the analysis, of which the clinical pathological features were summarized and analyzed statistically to determine the prognostic factors and the prognostic effect of anti-HER2 targeted therapy. Result Of the 50 patients, there were 13 cases(26%) with stage T_(1 a-1 b) disease, and 37 cases(74%) were in T_(1 c·) 4 cases of recurrence and metastasis were observed, and there was no death, all patients were followed for 6-36 months, and the median followup time was 22 months; There were significant differences between the number of patients with T_(1 a-1 b) and T_(1 c) disease regarding different histological grading, clinical stage, vascular invasion, axillary lymph node metastasis, Ki-67 status, and the administration of anti-HER2 targeted therapy(P0.05); Compared with those who did not receive the anti-HER2 targeted therapy(DFS=89.7%), there was neither recurrence nor metastasis in patients that received full anti-HER2 targeted therapy in 3 years after treatment(DFS= 100.0%), and the difference was statistically significant(P=0.046); There was statistically significant difference in DFS between patients with or without vascular invasion and axillary lymph node metastasis(P0.05); Cox multivariate analysis showed that,axillary lymph node metastasis was independent prognostic factors of stage T_1 HER2-positive breast cancer patients. Conclusion For stage T_1 HER2-positive breast cancer patients, the presence of axillary lymph node metastasis is an independent factor for the prognosis, and the anti-HER2 targeted therapy predicts good prognosis for stage T_1 HER2-positive breast cancer with vascular metastasis or axillary lymph node metastasis.
【CateGory Index】： R737.9